Pfizer ‘ready to roll’ if BioNTech COVID-19 shot is approvedPfizer now has hundreds of thousands of doses of BioNTech’s COVID-19 vaccine coming off the production line at Share XPfizer ‘ready to roll’ if BioNTech COVID-19 shot is approvedhttps://pharmaphorum.com/news/pfizer-ready-to-roll-if-biontech-covid-19-shot-is-approved/
FDA kicks off review of second kidney cancer combo based on BMS’ OpdivoBristol-Myers Squibb could be mere months away from claiming a second US approval for an Opdivo-based combination immunotherapy Share XFDA kicks off review of second kidney cancer combo based on BMS’ Opdivohttps://pharmaphorum.com/news/fda-starts-review-of-second-kidney-cancer-use-for-bms-opdivo/
Kite cues up first EMA okay for mantle cell lymphoma CAR-TGilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for Share XKite cues up first EMA okay for mantle cell lymphoma CAR-Thttps://pharmaphorum.com/news/kite-cues-up-first-ema-okay-for-mantle-cell-lymphoma-car-t/
Novartis’ big bet on inclisiran nears fruition, as CHMP backs drugNovartis’ near-$10 billion takeover of The Medicines Company last year was focused mainly on one asset – cholesterol-lowering Share XNovartis’ big bet on inclisiran nears fruition, as CHMP backs drughttps://pharmaphorum.com/news/novartis-big-bet-on-inclisiran-nears-fruition-as-chmp-backs-drug/
Boehringer, Yale trial digital tech in heart failurePatients with heart failure often have a dismal prognosis as the condition usually worsens over time, but a Share XBoehringer, Yale trial digital tech in heart failurehttps://pharmaphorum.com/news/boehringer-yale-trial-digital-tech-in-heart-failure/
Sanofi preps trials of second COVID-19 shot, as Russia approves anotherSanofi will shortly start human trials of a second coronavirus vaccine, developed with US biotech Translate Bio, after Share XSanofi preps trials of second COVID-19 shot, as Russia approves anotherhttps://pharmaphorum.com/news/sanofi-preps-trials-of-second-covid-19-shot-as-russia-approves-another/
NICE changes its mind on Novartis’ progressive MS drug MayzentUK cost-effectiveness agency NICE has backed Novartis’ Mayzent for secondary progressive multiple sclerosis (SPMS), after turning it down Share XNICE changes its mind on Novartis’ progressive MS drug Mayzenthttps://pharmaphorum.com/news/nice-changes-its-mind-on-novartis-progressive-ms-drug-mayzent/
Scynexis bids to end novel antifungal drought, filing ibrexafungerp in USScynexis has filed for FDA approval of its novel drug ibrexafungerp which – if approved – would be Share XScynexis bids to end novel antifungal drought, filing ibrexafungerp in UShttps://pharmaphorum.com/news/scynexis-bids-to-end-novel-antifungal-drought/
Blue Oak taps AI specialist Exscientia for CNS drug discoveryUS startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK Share XBlue Oak taps AI specialist Exscientia for CNS drug discoveryhttps://pharmaphorum.com/news/blue-oak-taps-ai-specialist-exscientia-for-cns-drug-discovery/
